AdminMed
Share
AdminPen has an annual worldwide market potential up to $2 billion. AdminPen™ device is a painless user-friendly inexpensive needle substitute based on the patented proprietary microneedle array. The microneedles are formed from a standard metal film that allows very robust and inexpensive manufacturing of the AdminPen. AdminPen device is attached to any standard commercially available pen with a
🚀 Exciting Publication Alert: AdminPatch 900 Microneedles Demonstrate Exceptional Drug Delivery Capabilities
We're thrilled to announce the publication of groundbreaking research featuring our AdminPatch 900 stainless steel microneedle arrays in the prestigious European Journal of Pharmaceutics and Biopharmaceutics!
This collaborative study, led by researchers from De Montfort University (UK), Aristotle University of Thessaloniki (Greece), Brunel University London, Nottingham Trent University, International Hellenic University, and University of Ulster, showcases the remarkable versatility of our microneedle technology for advanced drug delivery applications.
Key Performance Highlights of AdminPatch 900:
📍 Optimal Pe*******on: 800 μm-tall needles achieve 381 μm skin pe*******on depth with just 40N force, effectively reaching the dermis,
⚡ Dual Release Capability: Enables both rapid (100% in 2 hours) and sustained (100% over 7 days) drug release profiles,
🎯 High-Density Design: 900 microneedles per cm² maximize drug delivery efficiency,
💊 Superior Drug Loading: Achieves 94% drug release within 30 minutes for rapid formulations,
🔬 Proven Stability: Coatings maintain integrity for 10+ days, ensuring reliable shelf-life,
🏥 Medical-Grade Quality: SS316L stainless steel construction ensures biocompatibility and mechanical robustness.
This research demonstrates the unique capability of our microneedle arrays to encapsulate diverse drugs within polymeric matrices using electrohydrodynamic atomization, opening doors to personalized medicine and advanced therapeutic delivery systems.
Read the full paper: "Electrospinning/electrospraying coatings for metal microneedles: A design of experiments (DOE) and quality by design (QbD) approach"
http://www.adminmed.com/files/web/publications/2020-Electrospinning-electrospraying-coatings-for-metal-microneedles-Ahmad.pdf
🚀 Exciting Publication Alert: AdminPatch 900 Microneedles Demonstrate Exceptional Drug Delivery Capabilities
We're thrilled to announce the publication of groundbreaking research featuring our AdminPatch 900 stainless steel microneedle arrays in the prestigious European Journal of Pharmaceutics and Biopharmaceutics!
This collaborative study, led by researchers from De Montfort University (UK), Aristotle University of Thessaloniki (Greece), Brunel University London, Nottingham Trent University, International Hellenic University, and University of Ulster, showcases the remarkable versatility of our microneedle technology for advanced drug delivery applications.
Key Performance Highlights of AdminPatch 900:
📍 Optimal Pe*******on: 800 μm-tall needles achieve 381 μm skin pe*******on depth with just 40N force, effectively reaching the dermis,
⚡ Dual Release Capability: Enables both rapid (100% in 2 hours) and sustained (100% over 7 days) drug release profiles,
🎯 High-Density Design: 900 microneedles per cm² maximize drug delivery efficiency,
💊 Superior Drug Loading: Achieves 94% drug release within 30 minutes for rapid formulations,
🔬 Proven Stability: Coatings maintain integrity for 10+ days, ensuring reliable shelf-life,
🏥 Medical-Grade Quality: SS316L stainless steel construction ensures biocompatibility and mechanical robustness.
This research demonstrates the unique capability of our microneedle arrays to encapsulate diverse drugs within polymeric matrices using electrohydrodynamic atomization, opening doors to personalized medicine and advanced therapeutic delivery systems.
Read the full paper: "Electrospinning/electrospraying coatings for metal microneedles: A design of experiments (DOE) and quality by design (QbD) approach"
http://www.adminmed.com/files/web/publications/2020-Electrospinning-electrospraying-coatings-for-metal-microneedles-Ahmad.pdf
🚀 BREAKTHROUGH RESEARCH: AdminPatch® Microneedles Enable 29-Fold Enhancement in Alzheimer's Transdermal Drug Delivery
We're excited to share groundbreaking research published in the Journal of Drug Delivery Science and Technology demonstrating how our AdminPatch® microneedle arrays are revolutionizing drug delivery for Alzheimer's disease (AD) treatment.
The Challenge: Alzheimer's disease affects millions worldwide, causing progressive cognitive decline due to cholinergic dysfunction. While donepezil (DNP) improves patient outcomes, oral administration presents significant challenges:
* Patients with impaired cognitive function struggle with medication compliance
* Risk of overdosing or skipping doses
* Gastric side effects and non-specific interactions with peripheral nerves
* Need for daily pill management
The Innovation: Researchers at the National Institute of Technology Karnataka and Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, developed pH-sensitive niosomes loaded with donepezil and demonstrated successful transdermal delivery using our AdminPatch® microneedle arrays.
Remarkable Results:
✅ 29-fold enhancement: AdminPatch 1200 achieved a 26.46-fold increase in transdermal permeation compared to passive delivery
✅ Consistent delivery: Steady flux rate of 9.89 ± 0.923 μg/cm²/h for intact niosomes carrying donepezil
✅ Superior drug transport: MN1200 delivered 608.19 ± 15.6 μg of donepezil over 24 hours vs. only 23.43 ± 3.57 μg with passive delivery
✅ Enhanced permeability: Permeability coefficient of 995.15 × 10⁻⁵ cm/h with MN1200 vs. 24.40 × 10⁻⁵ cm/h passive delivery
✅ pH-responsive release: Smart niosomes maintain 82.15% ± 1.54% encapsulation efficiency and release drug in response to brain acidosis associated with AD
✅ Scalable options: Three needle lengths (AdminPatch 600, 777, and 1200) provide flexibility for optimized delivery
Why This Matters: This user-friendly transdermal approach offers a pragmatic alternative for AD patients with cognitive impairment, eliminating the need for daily oral medication while:
* Reducing gastric side effects
* Ensuring consistent drug delivery
* Enabling potential caregiver administration
* Improving patient compliance and quality of life
The Future of Alzheimer's Treatment: By combining our proven AdminPatch® microneedle technology with innovative nanocarrier systems, we're paving the way for more effective, patient-friendly treatments for neurodegenerative diseases.
📄 Read the full publication:
http://www.adminmed.com/files/web/publications/2020-Tailoring-solulan-C24-based-niosomes-for-transdermal-delivery-of-donepezil-Raval+.pdf
Congratulations to the research team at NITK and Manipal Academy for this outstanding contribution to Alzheimer's disease therapeutics!
🔬 Pioneering Research: AdminPen™ Delivers Breakthrough in Rheumatoid Arthritis Treatment!
We're excited to share a groundbreaking publication in the Journal of Drug Delivery Science and Technology showcasing our AdminPen™ 1200 technology in a revolutionary approach to rheumatoid arthritis management!
This landmark study by Zewail et al. (2025) from Harvard Medical School, Damanhour University, and Cairo University, presents the FIRST-EVER report of using hollow microneedle arrays to deliver Pluronic F127 nanohybrid hydrogels loaded with chondroitin sulphate-coated nanostructured lipid carriers containing pomegranate extract in an antigen-induced arthritis (AIA) rat model.
Exceptional in vivo results obtained with AdminPen™ 1200 hollow microneedle array injection devices:
✅ 100% pe*******on efficiency - All 43 hollow microneedles achieved complete skin pe*******on, ensuring reliable intradermal drug delivery to inflamed joints,
✅ Precise 1100-1200 μm pe*******on depth - Optimal breach of skin barriers for direct therapeutic delivery to target tissues,
✅ 75% reduction in TNF-α inflammatory markers - Achieved 42.6 pg/ml vs 173.5 pg/ml in untreated controls, demonstrating powerful anti-inflammatory action,
✅ 65% decrease in joint degradation (MMP-3) - Reduced to 10 Ng/ml from 29.2 Ng/ml, protecting against cartilage breakdown,
✅ Complete joint healing in 14 days - Full resolution of swelling with joint diameters normalized to healthy controls.
This pioneering research establishes AdminPen™ as a game-changing platform for minimally invasive, sustained-release therapies for the treatment of rheumatoid arthritis. By combining advanced nanomedicine with our hollow microneedle technology, we're opening new frontiers in targeted joint therapy with enhanced patient comfort and compliance.
Read the full publication:https://www.adminmed.com/files/web/publications/2025-Intradermal-delivery-of-nanohybrid-thermosensitive-hydrogels-loaded-with-chondroitin-sulphate-Zewail.pdf
Click here to claim your Sponsored Listing.
Category
Telephone
Website
Address
Houston, TX
77080
